Regeneron Pharmaceuticals said on Friday it would stop enrolling patients receiving advanced COVID-19 care in its trials testing its experimental antibody treatment, based on the recommendation of an independent data monitoring panel. The recommendation was based on a potential safety signal and an unfavorable risk/benefit profile at this time. The decision followed a similar suggestion for a rival Eli Lilly & Co treatment earlier this week. The committee backed the enrollment in non-hospitalized patients as well as hospitalized patients requiring either no or a low level of oxygen. Regeneron said it would inform the U.S. Food and Drug Administration, which is evaluating the treatment for a potential emergency use authorization in mild-to-moderate outpatients at high risk for poor outcome. —Reuters Staff Source
